Introduction
Early in the fall of 2009 (Table 1 ). In either case, a type II or type I error leads to an erroneous conclusion. Although infection is used as an example, these errors are applicable to a broad range of clinical situations.
Examples of Type I and Type II Errors
As highlighted in the example opening this article, the sensitivity of RIDTs for detecting novel influenza A (H1N1) can be as low as 10% (although there have been few studies to date). (1)(2) The low sensitivity results in a high likelihood of a false-negative result. Thus, any negative test result would have a high likelihood of being an erroneous result, that is, a type II error. In the example, the clinician chose not to conduct the RIDT for detecting novel influenza A (H1N1), in part, because of the likelihood of a type II error, choosing instead to treat the 22-month-old patient presumptively because he has been classified as a high-risk case due to his age. (4) The likelihood of a type II error, or false-negative, is the same reason that a backup throat culture was performed for GAS. Although the rapid test for GAS typically has a sensitivity of 80% or higher (and, thus, the likelihood of a false-negative is less than that associated with the RIDT), a backup culture is performed to ensure that the negative result is, indeed, a true negative.
In testing for GAS and influenza A (H1N1), the clinician was less concerned about the likelihood of a false-positive or a type I error. She was more concerned about missing a true infection, which might lead to complications of either acute rheumatic fever in the case of GAS or significant morbidity or complications due to the patient's young age in the case of novel influenza A (H1N1).
The opposite is true when testing for human immunodeficiency virus (HIV). When testing for HIV, there is great concern for making a type I error, that is, telling patients that they are infected when, in fact, they are not. Because HIV is a chronic disease that is not curable, a false-positive result can be extremely troubling to a patient. In contrast to the GAS diagnostic procedure, in which every negative test result prompts a confirmatory culture, every positive HIV result from a Western blot receives a confirmatory enzyme linked immunosorbent assay test. This second procedure is performed to reduce type I errors. Because an undiagnosed HIV infection will result in no treatment and may increase transmission risk, clinicians also have great concerns about type II errors, in which the diagnosis is missed.
Type I and Type II Errors in Research
When conducting research, the equivalent of a type II error in statistical terms is failing to reject the null hypothesis when it should have been rejected (Table 2) . (3)(5) For example, in the case of a randomized, controlled trial (RCT) designed to test the difference between therapy A and therapy B, a type II error would result in concluding that the two therapies were not different from each other when, in fact, they were different. The probability of a type II error often is denoted with the Greek letter beta. The probability that a study will conclude correctly that two therapies are different when they are, indeed, different equals 1Ϫbeta or the power of a study.
In statistical terms, the equivalent of a type I error is rejecting the null hypothesis when it should not have been rejected (Table 2) . (3)(5) A type I error in an RCT results in the conclusion that there was a difference between therapy A and therapy B when, in fact, the two therapies were not different. The probability of a type I error is often denoted with the Greek letter alpha. The alpha is probably most familiar as the P value of a study, which, by common convention, has been set at a significant value of 0.05. Setting the P value of a study at 0.05 means that the researchers are willing to accept a 5% probability of a type I error or a 5% probability that the results showing a difference could have occurred by chance alone. 
